Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 388 Colorectal Neoplasms 307 Rectal Neoplasms 225 Stomach Neoplasms 206 Pancreatic Neoplasms 137 Neoplasm Metastasis 121 Colonic Neoplasms 93 Neoplasms 85 Triple Negative Breast Neoplasms 63 Esophageal Neoplasms 57 Biliary Tract Neoplasms 37 Nasopharyngeal Carcinoma 36 Adenocarcinoma 31 Cholangiocarcinoma 30 Carcinoma, Hepatocellular 30 Gallbladder Neoplasms 28 Carcinoma, Non-Small-Cell Lung 21 Bile Duct Neoplasms 21 Locally Advanced Rectal Cancer 20 Adenocarcinoma Of Esophagus 20 Squamous Cell Carcinoma of Head and Neck 19 Gastrointestinal Neoplasms 18 Brain Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Liver Neoplasms 17 Head and Neck Neoplasms 17 Esophageal Squamous Cell Carcinoma 17 Ovarian Neoplasms 14 Colorectal Cancer Metastatic 14 Breast Neoplasms, Male 14

Interventions

eribulin 3 Vinorelbine 2 Paclitaxel 2 Epirubicin 2 Doxorubicin 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 anlotinib 1 Taxes 1 Precision Medicine 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × Capecitabine × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡